Sofinnova Converts Royalties to Equity, Director Resigns from Abivax Board
Summary
Sofinnova Crossover I SLP exchanged royalty certificates for $4.77 million in Abivax ADSs, increasing its voting stake to 6.7%, while its representative Kinam Hong resigned from the board.
Key Events · Ownership and Investor Activity · ABVX
-
Sofinnova's Equity Conversion
Sofinnova Crossover I SLP received 42,755 ADSs, valued at approximately $4.77 million, as part of Abivax's $90 million royalty certificate repurchase.
-
Increased Voting Stake
Following the transaction, Sofinnova's voting rights in Abivax increased to 6.7% of the outstanding shares.
-
Director Resignation
Kinam Hong, a member of Sofinnova's investment committee, resigned from Abivax's Board of Directors.
Analysis · ABVX · Life Sciences
This filing provides specific details on a significant capital event for Abivax, where it repurchased $90 million in royalty certificates, partly through issuing new shares. Sofinnova's participation in this transaction, converting its royalty interest into equity, updates its ownership structure and increases its voting stake to 6.7%. The simultaneous resignation of Kinam Hong, a representative of this major institutional investor, from the board is a notable governance change.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABVX was trading at $119.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.9B. The 52-week trading range was $5.59 to $148.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.